Biosimilars: Policy Developments and Emerging Competition Issues

This program will address recent developments relating to the unique challenges that follow-on biologics (also known as biosimilars) present for regulators, policymakers, and drugmakers. While biosimilars are not yet available in the U.S. market, sales have begun in Europe. Among other things, this panel will discuss Europe’s experience with biosimilars and implications that the European experience has for U.S. regulation and sales of biosimilars, expected to begin in 2015. Click “REGISTER NOW” button to register.